418 related articles for article (PubMed ID: 25361007)
21. BRAF, K-ras and BAT26 mutations in colorectal polyps and stool.
Jin YM; Li BJ; Qu B; Du YJ
World J Gastroenterol; 2006 Aug; 12(32):5148-52. PubMed ID: 16937524
[TBL] [Abstract][Full Text] [Related]
22. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression.
Calistri D; Rengucci C; Seymour I; Lattuneddu A; Polifemo AM; Monti F; Saragoni L; Amadori D
J Cell Physiol; 2005 Aug; 204(2):484-8. PubMed ID: 15702478
[TBL] [Abstract][Full Text] [Related]
23. The RAS-BRAF kinase pathway is not involved in uveal melanoma.
Kiliç E; Brüggenwirth HT; Verbiest MM; Zwarthoff EC; Mooy NM; Luyten GP; de Klein A
Melanoma Res; 2004 Jun; 14(3):203-5. PubMed ID: 15179189
[TBL] [Abstract][Full Text] [Related]
24. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
25. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
26. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
[TBL] [Abstract][Full Text] [Related]
27. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
[TBL] [Abstract][Full Text] [Related]
28. KRAS and BRAF: drug targets and predictive biomarkers.
Vakiani E; Solit DB
J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
[TBL] [Abstract][Full Text] [Related]
29. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
30. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.
Kotoula V; Sozopoulos E; Litsiou H; Fanourakis G; Koletsa T; Voutsinas G; Tseleni-Balafouta S; Mitsiades CS; Wellmann A; Mitsiades N
Endocr Relat Cancer; 2009 Jun; 16(2):565-72. PubMed ID: 19190079
[TBL] [Abstract][Full Text] [Related]
31. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
32. Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations.
Kim IJ; Kang HC; Jang SG; Kim K; Ahn SA; Yoon HJ; Yoon SN; Park JG
Carcinogenesis; 2006 Mar; 27(3):392-404. PubMed ID: 16219636
[TBL] [Abstract][Full Text] [Related]
33. Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases.
Ates O; Yalcin S
Indian J Cancer; 2019; 56(2):176-179. PubMed ID: 31062740
[TBL] [Abstract][Full Text] [Related]
34. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.
Ugurel S; Thirumaran RK; Bloethner S; Gast A; Sucker A; Mueller-Berghaus J; Rittgen W; Hemminki K; Becker JC; Kumar R; Schadendorf D
PLoS One; 2007 Feb; 2(2):e236. PubMed ID: 17311103
[TBL] [Abstract][Full Text] [Related]
35. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
[TBL] [Abstract][Full Text] [Related]
36. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation.
Nagasaka T; Sasamoto H; Notohara K; Cullings HM; Takeda M; Kimura K; Kambara T; MacPhee DG; Young J; Leggett BA; Jass JR; Tanaka N; Matsubara N
J Clin Oncol; 2004 Nov; 22(22):4584-94. PubMed ID: 15542810
[TBL] [Abstract][Full Text] [Related]
37. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
Zimmer L; Barlesi F; Martinez-Garcia M; Dieras V; Schellens JH; Spano JP; Middleton MR; Calvo E; Paz-Ares L; Larkin J; Pacey S; Venturi M; Kraeber-Bodéré F; Tessier JJ; Eberhardt WE; Paques M; Guarin E; Meresse V; Soria JC
Clin Cancer Res; 2014 Aug; 20(16):4251-61. PubMed ID: 24947927
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic strategies for targeting BRAF in human cancer.
Pratilas CA; Solit DB
Rev Recent Clin Trials; 2007 May; 2(2):121-34. PubMed ID: 18473997
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
Halilovic E; Solit DB
Curr Opin Pharmacol; 2008 Aug; 8(4):419-26. PubMed ID: 18644254
[TBL] [Abstract][Full Text] [Related]
40. BRAF and RAS mutations in human lung cancer and melanoma.
Brose MS; Volpe P; Feldman M; Kumar M; Rishi I; Gerrero R; Einhorn E; Herlyn M; Minna J; Nicholson A; Roth JA; Albelda SM; Davies H; Cox C; Brignell G; Stephens P; Futreal PA; Wooster R; Stratton MR; Weber BL
Cancer Res; 2002 Dec; 62(23):6997-7000. PubMed ID: 12460918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
